Suraksha Diagnostic lifts first-half asset purchases 43%

Suraksha Diagnostic Limited increased cash purchases of property, plant and equipment, other intangible assets and intangible assets under development by 43% to Rs 33.5905 crore in the six months ended September 30, 2026. Its property, plant and equipment balance rose 24% to Rs 240.9575 crore from Rs 193.5785 crore at March 31, 2026.

How much did Suraksha Diagnostic spend on capital assets?

Suraksha Diagnostic spent Rs 33.5905 crore on capital-asset purchases in the six months ended September 30, 2026, compared with Rs 23.4615 crore in the corresponding period a year earlier. The increase was Rs 10.129 crore, equivalent to approximately 43%, according to the consolidated cash-flow statement.

The cash-flow line includes capital work-in-progress, capital advances and capital creditors. It is therefore broader than a direct measure of additions to property, plant and equipment alone. The filing does not identify the diagnostic centres, pathology equipment, radiology equipment, projects or locations associated with the Rs 33.5905 crore outlay.

Suraksha Diagnostic also recorded Rs 15.9648 crore of investment in a company during the 2026 first half, compared with net redemption or investments in bank deposits of Rs 3.2023 crore in the prior-year period. Total net cash used in investing activities consequently rose to Rs 47.5702 crore from Rs 21.8053 crore. The disclosed investing cash flow does not provide a project-level allocation of either the capital purchases or the company investment.

How did Suraksha Diagnostic's owned asset base change?

Suraksha Diagnostic's property, plant and equipment increased by Rs 47.379 crore to Rs 240.9575 crore at September 30, 2026 from Rs 193.5785 crore at March 31, 2026. That 24% increase was accompanied by a decline in capital work-in-progress, or CWIP, of Rs 18.4166 crore over the same six-month period.

CWIP stood at Rs 16.6997 crore at September 30, 2026, down from Rs 35.1163 crore at March 31, 2026. The movement occurred alongside the increase in property, plant and equipment, but the filing does not state whether any specific CWIP projects were commissioned and transferred into that category. It also does not give a reconciliation between cash purchases and changes in balance-sheet asset values.

Total assets increased to Rs 520.697 crore at September 30, 2026 from Rs 448.1164 crore at March 31, 2026. The expansion was concentrated in non-current assets, which grew Rs 76.7489 crore, while current assets decreased by Rs 4.1682 crore to Rs 58.4084 crore. Cash and cash equivalents rose to Rs 5.6688 crore from Rs 3.2141 crore, but bank balances other than cash equivalents fell to Rs 11.4869 crore from Rs 23.1343 crore.

What changed in Suraksha Diagnostic's leased asset commitments?

Suraksha Diagnostic's combined lease liabilities increased by Rs 20.0165 crore to Rs 148.6252 crore at September 30, 2026 from Rs 128.6087 crore at March 31, 2026. Non-current lease liabilities accounted for Rs 133.6774 crore of the September balance and current lease liabilities for Rs 14.9478 crore.

Right-of-use assets, which reflect the accounting value of leased assets, rose Rs 17.4698 crore to Rs 133.5249 crore during the same period. The simultaneous growth in right-of-use assets and lease liabilities shows a larger reported leased-asset base. However, the filing does not identify the leased sites, lease terms, asset categories or whether additions relate to diagnostic facilities.

Suraksha Diagnostic's total borrowings also increased to Rs 6.4587 crore at September 30, 2026 from Rs 1.7344 crore at March 31, 2026. Non-current borrowings rose to Rs 4.5004 crore from Rs 0.1776 crore, while current borrowings rose to Rs 1.9583 crore from Rs 1.5568 crore. These balances are presented separately from lease liabilities in the consolidated balance sheet.

How did higher investment activity fit Suraksha Diagnostic's cash flow and earnings?

Suraksha Diagnostic generated Rs 58.7944 crore of net cash from operating activities in the six months ended September 30, 2026, up from Rs 36.6931 crore a year earlier. That operating inflow exceeded the Rs 47.5702 crore investing outflow, although financing activities used a further Rs 8.7695 crore, including Rs 13.8146 crore of lease-liability payments.

The group reported Rs 18.67165 crore of revenue from operations for the six months ended September 30, 2026, compared with Rs 151.3153 crore a year earlier. This figure converts to Rs 186.7165 crore, an increase of Rs 35.4012 crore. Profit before tax rose to Rs 35.3981 crore from Rs 24.5156 crore, while depreciation and amortisation expense rose to Rs 23.8897 crore from Rs 19.6257 crore.

Suraksha Diagnostic reports a single operating segment comprising diagnostic centres that provide pathology and radiology services. As a result, the filing does not separately show capital spending, revenue, profit or asset balances for pathology and radiology. The six subsidiaries included in the consolidated results had total assets of Rs 37.316 crore before consolidation adjustments at September 30, 2026, according to the auditor's review report.

Conclusion

Suraksha Diagnostic's first-half accounts show higher cash investment in physical and intangible assets, a Rs 47.379 crore rise in property, plant and equipment, and a Rs 20.0165 crore increase in lease liabilities. At the same time, CWIP declined by Rs 18.4166 crore, while operating cash flow increased to Rs 58.7944 crore and revenue from operations reached Rs 186.7165 crore.

The next disclosures to watch are whether Suraksha Diagnostic identifies the projects, sites or equipment behind its Rs 33.5905 crore asset-purchase line and the Rs 16.6997 crore CWIP balance. The September filing leaves unresolved how much of the CWIP reduction reflects completed projects, and it does not describe the leased assets underlying the higher lease liabilities.